Indian IBD market is estimated to grow significantly at a CAGR of around 6.2% during the forecast period. The Indian pharmaceutical industry has been consistently growing with the public and private investments, making India as a potential market for the treatment of prevailing diseases such as IBD. Additionally, healthcare expenditure is playing a critical role in fueling the IBD market in India. With the substantial healthcare expenditure and various insurance schemes including PMJAY and Ayushman Bharat-National Health Protection Mission, the healthcare sector is improving on various fronts in India. Various aspects in which the Indian healthcare sector is improving upon includes a number of healthcare services, advanced diagnostic centers, induction of advanced treatment process, international collaborations, and developing infrastructure for healthcare services that further provide a significant opportunity to the market growth.
Indian IBD market is segmented on the basis of disease type, diagnostics, and therapeutics. Indian IBD market is segmented on the basis of disease type into ulcerative colitis and Crohn’s disease. Crohn’s disease segment is estimated to dominate the market. The growth of the segment is attributed to the comparatively higher incidence of Crohn’s disease than ulcerative colitis. On the basis of diagnostics, the market is segmented into blood and stool, endoscopies, ultrasound, and X-rays. Endoscopy is a conventional diagnostic method that is widely being used for the diagnosis of IBD and having a considerable share in the market. The therapeutics segment is further segmented into anti-inflammatory drugs and surgery. There is a range of anti-inflammatory drugs used for the treatment of IBD, such as immunosuppressants (methotrexate, ciclosporin, and azathioprine), steroids and biological drugs. These are usually the first step in the treatment of IBD.
The companies which are contributing to the growth of the Indian IBD market include AbbVie Inc., Allergan, PLC, Boehringer Ingelheim International GmbH, Eli Lilly and Co., Daiichi Sankyo Co. Ltd., Mercator Pharmaceutical Solutions Johnson & Johnson Services Inc., Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Co., Ltd., RPG Life Sciences Ltd., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, and technological advancements to stay competitive in the market.
Research Methodology
The market study of Indian IBD market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.
Secondary Sources Include
Market Segmentation
The Report Covers
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. Indian IBD Market by Disease Type
5.1.1. Ulcerative Colitis
5.1.2. Crohn’s Disease
5.2. Indian IBD Market by Diagnostics
5.2.1. Blood and Stool Tests
5.2.2. Endoscopies,
5.2.3. Ultrasound
5.2.4. X-Ray
5.3. Indian IBD Market by Therapeutics
5.3.1. Surgery
5.3.2. Anti- Inflammatory Drug Administration
5.3.2.1. Steroids
5.3.2.2. Immunosuppressant
5.3.2.3. Biological Drugs
5.3.2.4. Amino salicylates
5.3.2.5. Others
6. Company Profiles
6.1. AbbVie Inc.
6.2. Allergan, PLC
6.3. Boehringer Ingelheim International GmbH
6.4. Daiichi Sankyo Co. Ltd.
6.5. Eli Lilly and Co.
6.6. Johnson & Johnson Services Inc.
6.7. Mercator Pharmaceutical Solutions
6.8. Pfizer Inc.
6.9. Sanofi S.A.
6.10. RPG Life Sciences Ltd.
6.11. Takeda pharmaceutical Co., Ltd.
1. INDIAN IBD MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2018-2025 ($ MILLION)
2. INDIAN IBD MARKET RESEARCH AND ANALYSIS BY DIAGNOSTICS, 2018-2025 ($ MILLION)
3. INDIAN IBD MARKET RESEARCH AND ANALYSIS BY THERAPEUTICS, 2018-2025 ($ MILLION)
1. INDIAN IBD MARKET SHARE BY DISEASE TYPE, 2018 VS 2025 (%)
2. INDIAN IBD MARKET SHARE BY DIAGNOSTICS, 2018 VS 2025 (%)
3. INDIAN IBD MARKET SHARE BY THERAPEUTICS, 2018 VS 2025 (%)